Oncolytics Biotech

Company snapshot

Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments.

• 23 active pipeline program(s) linked via ClinicalTrials.gov.
• 66 US patent(s) indexed to this assignee profile.
• 23 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Oncolytics Biotech. Not investment advice.

• Peer + 0 momentum

  First People's Hospital

  TA overlap score 50

• Peer + 0 momentum

  Eli Lilly and

  TA overlap score 42.4

• Peer + 0 momentum

  Chongqing Precision Biotech

  TA overlap score 40

• Peer + 0 momentum

  Chinese Academy of

  TA overlap score 40

• Peer + 0 momentum

  AbbVie Deutschland GmbH

  TA overlap score 40

• Peer + 0 momentum

  United Therapeutics Europe

  TA overlap score 40

• Peer + 0 momentum

  CORCEPT THERAPEUTICS

  TA overlap score 33.4

• Peer + 0 momentum

  INOVIO Pharmaceuticals

  TA overlap score 29.2

• Peer + 0 momentum

  HALOZYME THERAPEUTICS

  TA overlap score 29

• Peer + 0 momentum

  Alaunos Therapeutics

  TA overlap score 26.8

Recent activity

Latest pipeline, patent, and corporate events for Oncolytics Biotech.

1. Jun 8, 2026 Clinical update

   REO 029 — Phase 2

2. Jun 8, 2026 Clinical update

   Lenalidomide or Pomalidomide — Phase 1

3. Jun 8, 2026 Clinical update

   Docetaxel, Reolysin and Prednisone — Phase 2

4. Jun 5, 2026 Clinical update

   REOLYSIN® — Phase 1

5. May 23, 2026 Clinical update

   REOLYSIN — Phase 3

View all clinical trial activity →

• What is Oncolytics Biotech?

  Oncolytics Biotech is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker ONCY. Primary therapeutic focus areas include Recurrent Plasma Cell Myeloma, Anal Cancer Metastatic, Ras-mutated Metastatic Colorectal Cancer, Prostate Cancer, Colorectal

• Is Oncolytics Biotech publicly traded?

  Yes. Oncolytics Biotech is listed with ticker ONCY on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Oncolytics Biotech develop or market?

  We link 14 drug profile(s) where Oncolytics Biotech is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/oncolytics-biotech-inc#company-drugs.

• What are the latest developments for Oncolytics Biotech?

  In the last 12 months our linked public records show 23 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Oncolytics Biotech focus on?

  Oncolytics Biotech focuses on Recurrent Plasma Cell Myeloma, Anal Cancer Metastatic, Ras-mutated Metastatic Colorectal Cancer based on our analysis of their pipeline programs and drug development activities.